A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 909-914

  Cassier, P A ^a   Lefranc, A ^a   Y Amela, E ^b   Chevreau, C ^c   Bui, B N ^d   Lecesne, A ^e   Ray Coquard, I ^a   Chabaud, S ^a   Penel, N ^b,f   Berge, Y ^c   Domont J ^e   Italiano, A ^d   Duffaud, F ^g   Cadore, A C ^a   Polivka, V ^a   Blay, J Y ^a  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d INSTITUT BERGONIÉ   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIV LILLE   (France)

^g TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PANOBINOSTAT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXAMIC ACIDS; INDOLES; LEIOMYOSARCOMA; LIPOSARCOMA; LIPOSARCOMA, MYXOID; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; SALVAGE THERAPY; SARCOMA; SARCOMA, ALVEOLAR SOFT PART; SARCOMA, ENDOMETRIAL STROMAL; SARCOMA, SYNOVIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883187700     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.442     Document Type: Article

References (25)

1. Attia S, Mahoney MR, Okuno SH, Adkins D, Ahuja HG, Ducker TP, Maples WJ, Ochs L, Wentworth-Hartung NL, Erlichman C, Bailey HH (2011) A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. J Clin Oncol 29: 10075.
2. Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC, Henley KJ, Kile BT, Prince HM, Johnstone RW (2011) Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117: 3658-3668.
3. Blay JY, Van GM, Verweij J, van OosteromAT, Le CA, Oosterhuis JW, Judson I, Nielsen OS (2003) Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39: 64-69.
4. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
5. Claus R, Lubbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22: 6489-6496.
6. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147: 97-101.
7. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14: 4500-4510.
8. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H (2008) SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 216: 495-504.
9. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5: 2203-2210.
10. Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, Michels JJ, Blay JY, Coindre JM, Bui B (2010) Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 117: 1049-1054.
11. Ito T, Ouchida M, Ito S, Jitsumori Y, Morimoto Y, Ozaki T, Kawai A, Inoue H, Shimizu K (2004) SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Lab Invest 84: 1484-1490.
12. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, Ozaki T, Sonobe H, Inoue H, Shimizu K (2005) Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 224: 311-319.
13. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP (2003) Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 9: 5749-5755.
14. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, van HQ, Blay JY, Frisch J, Van GM, Hermans C, Van OA, Tursz T, Verweij J (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18: 2676-2684.
15. Levard A, Derbel O, Meeus P, Ranchere D, Ray-Coquard I, Blay JY, Cassier PA (2013) Outcome of patients with advanced solitary fibrous tumors: the Centre Leon Berard experience. BMC Cancer 13: 109.
16. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de RM, Poulin N, van Kessel AG, Nielsen TO (2008) Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 68: 4303-4310.
17. Owen LA, Kowalewski AA, Lessnick SL (2008) EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 3: e1965.
18. Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, Masson E, Culver KW, Burris HA, Beck J (2007) Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and nonhodgkin's lymphoma. J Clin Oncol 25: 3500.
19. Reichardt P (2012) The treatment of uterine sarcomas. Ann Oncol 23(Suppl 10): x151-x157.
20. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y, Iwamoto Y (2005) Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 116: 784-792.
21. Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, Broker B, Volker U, Beck JF (2007) Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 133: 847-858.
22. Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM (2010) EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 29: 4352-4361.
23. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO (2012) Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 21: 333-347.
24. Van Glabbeke M, Verweij J, Judson I, Nielsen OS (2002) Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38: 543-549.
25. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le CC, Shen A, Engert A (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30: 2197-2203.